Searched for:
(1 - 9 of 9)
document
Vernooij-van Langen, A.M.M. (author), van der Pal, S.M. (author), Reijntjens, A.J.T. (author), Loeber, J.G. (author), Dompeling, E. (author), Dankert-Roelse, J.E. (author)
Background: False-positive screening results in newborn screening for cystic fibrosis may lead to parental stress, family relationship problems and a changed perception of the child's health. Aim of the study: To evaluate whether parental anxiety induced by a false positive screening result disappears after six months and to assess whether a...
article 2014
document
van der Ploeg, C.P.B. (author), van den Akker-van Marle, M.E. (author), Vernooij-van Langen, A.M.M. (author), Elvers, L.H. (author), Gille, J.J.P. (author), Verkerk, P.H. (author), Dankert-Roelse, J.E. (author), Loeber, J.G. (author), Triepels, R.H. (author), van der Pal, S.M. (author), Dompeling, E. (author), Pals, G. (author), Gulmans, V.A.M. (author), Oey-Spauwen, M.J.W. (author), Wijnands, Y.H.H.M. (author), Castricum, L.M. (author), Arets, H.G.M. (author), van der Ent, C.K. (author), Tiddens, H.A.W.M. (author), de Rijke, Y.B. (author), Yntema, J.B. (author)
BACKGROUND: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. METHODS: We used primary data to compare cost-effectiveness of four screening strategies for NBSCF, i.e. immunoreactive trypsinogen...
article 2015
document
van Dommelen, P. (author), Verkerk, P.H. (author), van Straaten, H.L. (author)
Objective To gain insight into health and related costs associated with very preterm births, one needs accurate information about the prevalence of the disabling conditions, including neonatal hearing loss (NHL). Study design We assessed the prevalence of NHL by week of gestation and categories of birth weight in very preterm neonates. Results...
article 2015
document
Zwaveling-Soonawala, N. (author), Trotsenburg, A.S. (author), Verkerk, P.H. (author)
Congenital hypothyroidism (CH) may be of thyroidal (CHT) or central origin (CHC). Worldwide, most neonatal screening programs are TSH based and effectively detect CHT. Only a few screening programs measure total or free T4 and TSH simultaneously or stepwise, enabling detection of CHT as well as CHC. A frequently used argument against screening...
article 2015
document
Zwaveling-Soonawala, N. (author), Trotsenburg, A.S. (author), Verkerk, P.H. (author)
Context. In central hypothyroidism (CeH) free thyroxine (FT4) concentrations are low while TSH concentrations may be low, normal or even slightly elevated due to reduced bioactivity. Congenital CeH (CCeH) may be isolated or part of multiple pituitary hormone deficiency (MPHD). Objective. To test our hypotheses that (1) TSH concentrations have a...
article 2018
document
Blom, M. (author), Bredius, R.G.M. (author), Weijman, G. (author), Dekkers, E.H.B.M. (author), Kemper, E.A. (author), van den Akker-van Marle, M.E. (author), van den Ploeg, C.P.B. (author), van der Burg, M. (author), Schielen, P.C.J.I. (author)
The implementation of newborn screening for severe combined immunodeficiency (SCID) in the Netherlands is a multifaceted process in which several parties are involved. The Dutch Ministry of Health adopted the advice of the Dutch Health Council to include SCID in the Dutch newborn screening program in 2015. As newborn screening for SCID is...
article 2018
document
Dankert-Roelse, J.E. (author), Bouvs, M.J. (author), Jakobs, B.S. (author), Janssens, H.M. (author), de Winter-de Groot, K.M. (author), Schonbeck, Y. (author), Gille, J.J.P. (author), Gulmans, V.A.M. (author), Verschoof-Puite, R.K. (author), Schielen, P.C.J.I. (author), Verkerk, P.H. (author)
Background Newborn screening for cystic fibrosis (NBSCF) was introduced in the Dutch NBS program in 2011 with a novel strategy. Methods Dutch NBSCF consisted of four steps: immuno-reactive trypsin (IRT), Pancreatitis-associated Protein (PAP), DNA analysis by Inno-LiPa (35 mutations), extended gene analysis (EGA) as fourth step and as safety net....
article 2019
document
van der Ploeg, C.P.B. (author), Blom, M. (author), Bredius, R.G.M. (author), van der Burg, M. (author), Schielen, P.C.J.I. (author), Verkerk, P.H. (author), van den Akker-van Marle, M.E. (author)
Severe combined immunodeficiency (SCID) is a condition that often results in severe infections and death at young age. Early detection shortly after birth, followed by treatment before infections occur, largely increases the chances of survival. As the incidence of SCID is low, assessing cost-effectiveness of adding screening for SCID to the...
article 2019
document
Cacciatore, P. (author), Visser, L.A. (author), Buyukkaramikli, N. (author), van der Ploeg, C.P.B. (author), van den Akker-van Marle, M.E. (author)
Introduction: Cost-effectiveness (CEA) and cost–utility analyses (CUA) have become popular types of economic evaluations (EE) used for evidence-based decision-making in healthcare resource allocation. Newborn screening programs (NBS) can have significant clinical benefits for society, and cost-effectiveness analysis may help to select the...
article 2020
Searched for:
(1 - 9 of 9)